What Is Cyclosporine and Why Is It Used?
Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation and is used primarily to prevent organ rejection after transplantation and to manage severe autoimmune diseases. It is available in oral capsules, an oral solution, and an intravenous formulation. Because of its narrow therapeutic window, use requires careful dose titration and regular laboratory monitoring.
More from this site
Keep reading the latest coverage
Common Indications for Cyclosporine Use
The main clinical contexts where cyclosporine is prescribed include:
- Prophylaxis of renal, hepatic, cardiac, and lung transplant rejection
- Treatment of severe, refractory psoriasis and psoriatic arthritis
- Management of atopic dermatitis unresponsive to topical therapies
- Rheumatoid arthritis and other inflammatory conditions when conventional therapy fails
- Certain cases of aplastic anemia and other bone marrow disorders
Dosing and Administration
Cyclosporine dosing varies widely depending on the condition, the organ transplanted, concurrent medications, and individual pharmacokinetics. For transplant patients, typical oral maintenance doses range from 3 to 10 mg per kilogram per day, divided into two doses. In autoimmune indications, lower doses are often used, and many clinicians prefer the oral solution for more precise titration. Cyclosporine should be taken at the same times each day, ideally on a consistent schedule relative to meals, because food can alter absorption.
Drug Interactions That Affect Cyclosporine Use
Cyclosporine is metabolized by CYP3A4 and is a substrate of P-glycoprotein, making it susceptible to numerous drug interactions. Potent CYP3A4 inhibitors such as ketoconazole, clarithromycin, and grapefruit juice can raise cyclosporine levels and increase toxicity risk. Conversely, inducers like rifampin, St. John's wort, and certain anticonvulsants can lower levels and compromise efficacy. Other important interactions include:
- NSAIDs and aminoglycosides, which may worsen kidney function
- Statins and other drugs that increase the risk of myopathy or rhabdomyolysis
- Live vaccines, which are generally contraindicated during treatment
Monitoring Parameters
Regular monitoring is essential to balance efficacy and safety. Key parameters include:
| Parameter | Typical Target Range or Goal | Context |
|---|---|---|
| Trough concentration (C0) | 100–400 ng/mL for most transplant protocols; varies by indication | Drawn 30 minutes before the next dose |
| Serum creatinine and BUN | Stable within baseline range | Warrants dose adjustment if rising |
| Blood pressure | Below individualized target | Hypertension is common and often requires treatment |
| Potassium and magnesium | Within normal limits | Hyperkalemia and hypomagnesemia are frequent |
| Liver enzymes | Stable or non-elevated | Elevations may signal hepatotoxicity |
Side Effects and Long-Term Risks
Common adverse effects of cyclosporine use include tremor, headache, gingival hyperplasia, hirsutism, and hypertension. Nephrotoxicity is the most serious concern, particularly with prolonged use, and can manifest as a rise in serum creatinine or a reduction in glomerular filtration rate. Other important risks include hyperkalemia, hypomagnesemia, hyperlipidemia, and an increased susceptibility to infections. Long-term use is also associated with a modestly elevated risk of certain malignancies, particularly skin cancers and lymphoma, which warrants ongoing dermatologic surveillance.
Practical Guidance for Patients
Patients on cyclosporine should adhere to a consistent daily routine for dosing, avoid grapefruit and grapefruit juice, and inform all healthcare providers—including dentists and pharmacists—about their cyclosporine use. Blood tests should not be skipped, even when the patient feels well, because toxicity can be silent. Any signs of infection, unusual bruising, or changes in urine output should prompt immediate medical review.
Cyclosporine Use in Special Populations
Dosing and monitoring in special populations require extra caution. In pediatric transplant recipients, weight-based dosing and frequent level checks are standard. In elderly patients, reduced renal function often necessitates lower starting doses. Hepatic impairment can alter cyclosporine metabolism, and pregnancy requires a careful risk-benefit assessment. In each of these situations, therapeutic drug monitoring guides safe and effective use.